Skip to content

Advocacy at a Glance

May 5, 2017

Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA.

  • FY 17 Omnibus Becomes Law; Brings Funding Support for FDA. We are pleased that FDA continues to make progress with its taxpayer-funded budget authority appropriations. The Omnibus legislation contains a net of $39 million in new BA funding for FDA. In addition, Congress previously appropriated $20 million in Cures funding for FY 17. Section 752 of the Omnibus also includes $10 million in no-year money for FDA efforts to combat Zika and other emerging threats. Altogether, this represents nearly a $70 million increase over FDA’s FY 16 appropriation.

Of the new monies, $35.7 million is to support the implementation of the Food Safety Modernization Act (FSMA). Of this amount, $18.7 million is provided for the National Integrated Food Safety System and $16.9 million is provided for import safety.  Congress also provided an increase of $10.9 million for medical product safety initiatives including $2.5 million for efforts to support the Precision Medicine initiative and provided an increase of $4.4 million animal drug and medical device review activities. An additional $2.5 million is added to monies for foreign high-risk inspections. The Committees accepted an offset of $13.5 million in administrative savings identified by FDA, leaving the net increase of $39 million. More details are on pages 28-31 at Omnibus report.

  • Two Additional Omnibus Provisions Help FDA. Through Report Language, the Appropriations Committees directed USDA and FDA not to adjust their current staffing levels based on the President’s Budget Request, which should be released soon. This undercuts an OMB memorandum ordering agencies to begin such adjustments in anticipation of having dramatically lower funding levels in FY 18. In addition, Section 716 of the Omnibus bill limits FDA’s ability to propose new user fees in lieu of budget authority appropriations, unless the budget request specifies which existing programs will be cut if the user fee revenue doesn’t materialize. These two provisions, very important for FDA, are discussed in more detail in this week’s Analysis and Commentary.

 

Comments are closed.